Skip to main content
. 2021 Jul 15;7(9):1368–1377. doi: 10.1001/jamaoncol.2021.2209

Figure 3. Overall Survival by Tumor Mutational Burden (TMB) and Programmed Death-Ligand 1 (PD-L1) Subsets Survival .

Figure 3.

A, Nivolumab vs nivolumab plus ipilimumab by TMB in patients with PD-L1 < 1%. B, Nivolumab vs nivolumab plus ipilimumab by TMB in patients with PD-L1 ≥ 1%. Tick marks represent censored observations.